<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472797</url>
  </required_header>
  <id_info>
    <org_study_id>27955</org_study_id>
    <nct_id>NCT00472797</nct_id>
  </id_info>
  <brief_title>Rebif New Formulation (RNF) Quality of Life (QOL) Study</brief_title>
  <acronym>RebiQoL</acronym>
  <official_title>A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and
      injection site redness Rebif treated subjects with relapsing forms of MS who transition to a
      new formulation of Rebif (RNF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ)</measure>
    <time_frame>% change from Baseline to Week 12</time_frame>
    <description>The MSTCQ Global Side Effect domain assesses the degree of satisfaction on global side effect questions 9, 10 &amp; 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied). Percent change calculated as 100% * (score at week 12 - score at baseline) / score at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Score for Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The MSTCQ Global Side Effect domain assesses the subjects degree of satisfaction on global side effect questions 9, 10 &amp; 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score From Baseline to Week 12 for All Domains Other Than Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The MSTCQ in all domains assesses quality of life. The score for all domains other than the Global Side Effect ranges from 17 (most favorable) to 85 (least favorable). Change calculated as (score at week 12 - score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Score on Short-Form McGill Pain Questionnaire (SF-MPQ): Change in Baseline to Wk 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The SF-MPQ assesses Tolerability of Pain with 15 questions to evaluate the type and severity of pain experienced 60 minutes after an injection of study drug. Scores range from 0 (no pain) to 45 (severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability in Pain Using Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The SF-MPQ included a visual analog scale, ranging from 0 to 100 mm, on which subjects rate pain from no pain (0 mm) to worst possible pain (100 mm). A rating of &lt;5 mm was considered pain-free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability - Redness at Injection Site</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
    <description>Change in Baseline to Week 12 Last Observation Carried Forward(LOCF)- A blinded assessment of injection site redness was conducted by a health care professional (1-72 hours) after the most recent injection measuring redness at its widest diameter in mm. Diameter of Redness, lower is better.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SF-36 Physical and Mental Component Scores</measure>
    <time_frame>Change from Baseline to Each Visit</time_frame>
    <description>Change from Baseline to each visit for Physical and Mental Component scores for SF-36. Score is norm-based with a mean of 50 and a standard deviation of 10.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rebif New Formulation - Non Titrated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rebif New Formulation - Titrated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif New Formulation Non Titrated</intervention_name>
    <description>human interferon beta 1a - Rebif New Formulation</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif New Formulation Titrated</intervention_name>
    <description>Human interferon beta 1a Rebif New Formulation</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject with a relapsing form of MS; diagnosis of MS is in accordance with the
             McDonald criteria

          2. Subject currently taking Rebif 44mcg tiw, and has been on this treatment for at least
             6 months (24 weeks) prior to study enrollment

          3. Subject currently using Rebiject II and 29 gauge needle

          4. Subject is between 18 and 60 years old inclusive

          5. Subject is able to read and understand English

          6. Subject is willing to follow study procedures

          7. Subject has given written informed consent and signed HIPAA

          8. Female subjects must not be either pregnant or breast-feeding and must lack
             childbearing potential, as defined by either: i) Being post-menopausal or surgically
             sterile, or ii) Using a hormonal contraceptive, intra-uterine device, diaphragm with
             spermicide, or condom with spermicide, for the duration of the study. (Confirmation
             required within 30 days prior to start of the study)

        Exclusion Criteria:

          1. Use of any other injectable medications on a regular basis during the week prior to
             the screening period or during the screening or treatment periods. Receiving a single
             injection for treatment or prophylaxis of a condition unrelated to the subject's
             multiple sclerosis or the subject's Rebif® therapy (e.g., receiving a influenza or
             pneumococcus vaccination) is acceptable

          2. Subject receiving MS therapy in addition (i.e., combination therapy) to Rebif® within
             3 months prior to study enrollment or at any time during study protocol.

          3. Subjects who have previously been on Rebif New Formulation (RNF).

          4. Subject with progressive forms of Multiple Sclerosis (MS).

          5. Subject with history of any chronic pain syndrome.

          6. Subject has any other disease apart from MS that could better explain the subjects
             signs and symptoms.

          7. Subject has complete transverse myelitis or bilateral optic neuritis.

          8. Subjects that use any investigational drug or experimental procedure within 12 weeks
             of visit 1.

          9. Subject received oral or systemic corticosteroids or ACTH within 30 days of visit 1
             (prior to enrollment).

         10. Subject has inadequate liver function, defined by a total bilirubin, aspartate
             aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase &gt; 2.5
             times the upper limit of the normal values.

         11. Subject has inadequate bone marrow reserve, defined as a white blood cell count less
             than 0.5 x lower limit of normal.

         12. Subject suffers from other current autoimmune disease.

         13. Subject suffers from major medical or psychiatric illness that in the opinion of the
             investigator creates undue risk to the subject or could affect compliance with the
             study protocol

         14. Subject is pregnant or attempting to conceive

         15. Visual or physical impairment that precludes completion of diaries and questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Dangond, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EMD Serono, Inc.</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <zip>02370</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mslifelines.com</url>
    <description>Full FDA approved prescribing information can be found here</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2007</study_first_submitted>
  <study_first_submitted_qc>May 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <results_first_submitted>February 18, 2009</results_first_submitted>
  <results_first_submitted_qc>July 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2009</results_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <name_title>Ahmad Al-Sabbagh, Vice President Medical Affairs, US Neurology</name_title>
    <organization>EMD Serono, Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>232 subjects were recruited from 25 Multiple Sclerosis (MS) Clinics in the US from April 2007 through November 2007.</recruitment_details>
      <pre_assignment_details>Run-in period (up to 30 days) on Rebif® 44 mcg tiw: The run-in period included a Screening Visit; assessments consisted of informed consent, medical/disease history, physical exam and laboratory assessments which were performed in the two-week period prior to Study Day 1, (prior to the first dose of a new formulation of rebif)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>New Formulation of Rebif - Non-Titrated</title>
          <description>The new formulation of rebif is not approved and under investigation in the US</description>
        </group>
        <group group_id="P2">
          <title>New Formulation of Rebif - Titrated</title>
          <description>The new frmulation of rebif is not approved and under investigation in the US</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Formulation of Rebif - Non-Titrated</title>
        </group>
        <group group_id="B2">
          <title>New Formulation of Rebif - Titrated</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="232.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="9.0"/>
                    <measurement group_id="B2" value="42.8" spread="9.4"/>
                    <measurement group_id="B3" value="43.7" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="180.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="232.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ)</title>
        <description>The MSTCQ Global Side Effect domain assesses the degree of satisfaction on global side effect questions 9, 10 &amp; 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied). Percent change calculated as 100% * (score at week 12 – score at baseline) / score at baseline.</description>
        <time_frame>% change from Baseline to Week 12</time_frame>
        <population>Safety: This population includes all subjects who received at least one dose of study drug. To explain difference in number, 1 subject lost to follow-up, 1 subject withdrew consent</population>
        <group_list>
          <group group_id="O1">
            <title>All New Formulation of Rebif Subjects</title>
            <description>All subjects combined in Intent to Treat (ITT) Population</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ)</title>
          <description>The MSTCQ Global Side Effect domain assesses the degree of satisfaction on global side effect questions 9, 10 &amp; 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied). Percent change calculated as 100% * (score at week 12 – score at baseline) / score at baseline.</description>
          <population>Safety: This population includes all subjects who received at least one dose of study drug. To explain difference in number, 1 subject lost to follow-up, 1 subject withdrew consent</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A one-sided paired t-test across all subjects by combining the titrated and non-titrated new formulation groups was performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value denotes percent change from baseline to week 12 for all combined subjects.</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>mean</param_type>
            <param_value>2.73</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>2.73</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Score for Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)</title>
        <description>The MSTCQ Global Side Effect domain assesses the subjects degree of satisfaction on global side effect questions 9, 10 &amp; 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent to Treat (ITT) and Last Observation Carried Forward (LOCF) Higher scores indicate a more favorable response</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O2">
            <title>Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O3">
            <title>All New Formulation of Rebif Subjects</title>
            <description>All subjects combined in Intent to Treat (ITT) Population</description>
          </group>
        </group_list>
        <measure>
          <title>Total Score for Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)</title>
          <description>The MSTCQ Global Side Effect domain assesses the subjects degree of satisfaction on global side effect questions 9, 10 &amp; 11 on a scale from 3 (not at all satisfied) to 15 (extremely satisfied).</description>
          <population>Intent to Treat (ITT) and Last Observation Carried Forward (LOCF) Higher scores indicate a more favorable response</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean GSE at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="1.7"/>
                    <measurement group_id="O2" value="13.4" spread="1.8"/>
                    <measurement group_id="O3" value="13.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean GSE at Week 12 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="1.6"/>
                    <measurement group_id="O2" value="13.8" spread="1.6"/>
                    <measurement group_id="O3" value="13.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Change - Baseline to Week 12 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="16.5"/>
                    <measurement group_id="O2" value="4.5" spread="18.8"/>
                    <measurement group_id="O3" value="5.0" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.466</p_value>
            <p_value_desc>P-value denotes difference between treatment groups</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value denotes the mean percent change from baseline to week 12.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value denotes the mean percent change from baseline to week 12.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score From Baseline to Week 12 for All Domains Other Than Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)</title>
        <description>The MSTCQ in all domains assesses quality of life. The score for all domains other than the Global Side Effect ranges from 17 (most favorable) to 85 (least favorable). Change calculated as (score at week 12 – score at baseline.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O2">
            <title>Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O3">
            <title>All New Formulation of Rebif Subjects</title>
            <description>All subjects combined in Intent to Treat (ITT) Population</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score From Baseline to Week 12 for All Domains Other Than Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)</title>
          <description>The MSTCQ in all domains assesses quality of life. The score for all domains other than the Global Side Effect ranges from 17 (most favorable) to 85 (least favorable). Change calculated as (score at week 12 – score at baseline.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection System Satisfaction Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="4.0"/>
                    <measurement group_id="O2" value="-2.9" spread="4.1"/>
                    <measurement group_id="O3" value="-3.1" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side Effects Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="6.4"/>
                    <measurement group_id="O2" value="-2.3" spread="5.7"/>
                    <measurement group_id="O3" value="-2.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu-Like Systems Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.6"/>
                    <measurement group_id="O2" value="-0.8" spread="3.6"/>
                    <measurement group_id="O3" value="-0.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection Site Reactions Domain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="3.2"/>
                    <measurement group_id="O2" value="-1.3" spread="2.9"/>
                    <measurement group_id="O3" value="-1.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Scores in all above Domains</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="8.8"/>
                    <measurement group_id="O2" value="-5.3" spread="7.6"/>
                    <measurement group_id="O3" value="-6.0" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in total score from baseline to week 12 for all subjects combined. Lower scores indicate a more favorable response</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value refers to change in total score from baseline to week 12 for all domains, except global side effect score, in the MSTCQ for all subjects combined.</p_value_desc>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test for change from baseline to week 12</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis evaluated differences between treatment groups in change in total score from baseline to week 12 for all domains, except global side effect score, in the MSTCQ. Lower scores indicate a more favorable response.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.110</p_value>
            <p_value_desc>P-value refers to differences between treatment groups in change in total score from baseline to week 12 for all domains, except global side effect score, in the MSTCQ.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Score on Short-Form McGill Pain Questionnaire (SF-MPQ): Change in Baseline to Wk 12</title>
        <description>The SF-MPQ assesses Tolerability of Pain with 15 questions to evaluate the type and severity of pain experienced 60 minutes after an injection of study drug. Scores range from 0 (no pain) to 45 (severe pain).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT and LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O2">
            <title>Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O3">
            <title>All New Formulation of Rebif Subjects</title>
            <description>All subjects combined in Intent to Treat (ITT) Population</description>
          </group>
        </group_list>
        <measure>
          <title>Total Score on Short-Form McGill Pain Questionnaire (SF-MPQ): Change in Baseline to Wk 12</title>
          <description>The SF-MPQ assesses Tolerability of Pain with 15 questions to evaluate the type and severity of pain experienced 60 minutes after an injection of study drug. Scores range from 0 (no pain) to 45 (severe pain).</description>
          <population>ITT and LOCF</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.4"/>
                    <measurement group_id="O2" value="1.1" spread="3.9"/>
                    <measurement group_id="O3" value="0.9" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis evaluates total score from baseline to week 12 for differences between each treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.302</p_value>
            <p_value_desc>P-value refers to differneces in total score from baseline to week 12 between treatment groups.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability in Pain Using Visual Analog Scale (VAS)</title>
        <description>The SF-MPQ included a visual analog scale, ranging from 0 to 100 mm, on which subjects rate pain from no pain (0 mm) to worst possible pain (100 mm). A rating of &lt;5 mm was considered pain-free.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O2">
            <title>Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O3">
            <title>All New Formulation of Rebif Subjects</title>
            <description>All subjects combined in Intent to Treat (ITT) Population</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability in Pain Using Visual Analog Scale (VAS)</title>
          <description>The SF-MPQ included a visual analog scale, ranging from 0 to 100 mm, on which subjects rate pain from no pain (0 mm) to worst possible pain (100 mm). A rating of &lt;5 mm was considered pain-free.</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - No. of Subjects Pain Free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 - No. of Subjects Pain Free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability - Redness at Injection Site</title>
        <description>Change in Baseline to Week 12 Last Observation Carried Forward(LOCF)- A blinded assessment of injection site redness was conducted by a health care professional (1-72 hours) after the most recent injection measuring redness at its widest diameter in mm. Diameter of Redness, lower is better.</description>
        <time_frame>Baseline to Week 12 (LOCF)</time_frame>
        <population>ITT and LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O2">
            <title>Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O3">
            <title>All New Formulation of Rebif Subjects</title>
            <description>All subjects combined in Intent to Treat (ITT) Population</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability - Redness at Injection Site</title>
          <description>Change in Baseline to Week 12 Last Observation Carried Forward(LOCF)- A blinded assessment of injection site redness was conducted by a health care professional (1-72 hours) after the most recent injection measuring redness at its widest diameter in mm. Diameter of Redness, lower is better.</description>
          <population>ITT and LOCF</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="27.7"/>
                    <measurement group_id="O2" value="-3.1" spread="28.2"/>
                    <measurement group_id="O3" value="-2.7" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis evaluates differences between treatment groups in change in diameter of injection site redness from baseline to week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.899</p_value>
            <p_value_desc>P-value denotes differences between treatment groups in change in diameter of injection site redness from baseline to week 12.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SF-36 Physical and Mental Component Scores</title>
        <description>Change from Baseline to each visit for Physical and Mental Component scores for SF-36. Score is norm-based with a mean of 50 and a standard deviation of 10.</description>
        <time_frame>Change from Baseline to Each Visit</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O2">
            <title>Titrated</title>
            <description>New formulation of rebif</description>
          </group>
          <group group_id="O3">
            <title>All New Formulation of Rebif Subjects</title>
            <description>All subjects combined in Intent to Treat (ITT) Population</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 Physical and Mental Component Scores</title>
          <description>Change from Baseline to each visit for Physical and Mental Component scores for SF-36. Score is norm-based with a mean of 50 and a standard deviation of 10.</description>
          <population>ITT</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Component Score - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" spread="9.4"/>
                    <measurement group_id="O2" value="43.6" spread="9.3"/>
                    <measurement group_id="O3" value="43.5" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component -Change from Baseline to Wk 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="5.7"/>
                    <measurement group_id="O2" value="2.0" spread="4.3"/>
                    <measurement group_id="O3" value="1.9" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component -Change from Baseline to Wk 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="7.7"/>
                    <measurement group_id="O2" value="1.5" spread="6.0"/>
                    <measurement group_id="O3" value="0.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component -Baseline to Ext. Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="6.5"/>
                    <measurement group_id="O2" value="1.7" spread="6.6"/>
                    <measurement group_id="O3" value="1.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component -Baseline to Ext Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="6.5"/>
                    <measurement group_id="O2" value="2.0" spread="6.4"/>
                    <measurement group_id="O3" value="1.5" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component -Baseline to Exit Visit/LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="6.4"/>
                    <measurement group_id="O2" value="1.4" spread="6.4"/>
                    <measurement group_id="O3" value="0.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component - Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="10.9"/>
                    <measurement group_id="O2" value="46.1" spread="10.9"/>
                    <measurement group_id="O3" value="46.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component - Change from Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="8.7"/>
                    <measurement group_id="O2" value="1.3" spread="9.1"/>
                    <measurement group_id="O3" value="1.9" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component - Change from Baseline to Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="10.6"/>
                    <measurement group_id="O2" value="-0.8" spread="10.0"/>
                    <measurement group_id="O3" value="0.5" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component - Baseline to Ext Visit 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="10.7"/>
                    <measurement group_id="O2" value="-1.2" spread="8.9"/>
                    <measurement group_id="O3" value="-0.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component - Baseline to Ext Visit 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="11.2"/>
                    <measurement group_id="O2" value="0.1" spread="10.4"/>
                    <measurement group_id="O3" value="0.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component - Baseline to Exit/LOCF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="11.2"/>
                    <measurement group_id="O2" value="0.1" spread="9.7"/>
                    <measurement group_id="O3" value="0.0" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component - Change from Baseline to Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component - Change from Baseline to Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component - Change from Baseline to Extension Visit 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component - Change from Baseline to Extension Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component - Change from Baseline to Exisit Visit LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component - Baseline to Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component - Baseline to Week 36</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.468</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component - Change from Baseline to Extension Visit 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline to Extension Visit 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.414</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline to Exit Visit LOCF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.991</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Non-Titrated</title>
          <description>New formulation of rebif</description>
        </group>
        <group group_id="E2">
          <title>Titrated</title>
          <description>New formulation of rebif</description>
        </group>
        <group group_id="E3">
          <title>All New Formulation of Rebif Subjects</title>
          <description>All subjects combined in Intent to Treat (ITT) Population</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Artrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">Cardiomiopathy</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyrotoxic crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangiopericytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Renal Artery Fibromuscular Dysplasia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Cellulitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Suicidal ideation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 10.0">Secondary Hypertension</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="118"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Influenza-like Illness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="118"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="113"/>
                <counts group_id="E3" events="36" subjects_affected="36" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="118"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="118"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="113"/>
                <counts group_id="E3" events="66" subjects_affected="66" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="118"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="118"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Neither Institution nor any Principal Investigators shall publish or present any results from such Study to any third parties until: (i) EMD Serono publishes the results from all sites participating in such Study; (ii) Institution receives notification from EMD Serono that publication of the multi-site results is no longer planned; or (iii) twenty-four (24) months following the completion of the multi-site study at all sites, whichever occurs first.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fernando Dangond, MD</name_or_title>
      <organization>EMD Serono, INc.</organization>
      <phone>781 681 2348</phone>
      <email>fernando.dangond@emdserono.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

